Equine infectious anemia virus-infected dendritic cells retain antigen presentation capability.

The research examines how the Equine Infectious Anemia Virus (EIAV) affects dendritic cells (DC) in horses. It found that these cells, even when infected with EIAV, continue to present antigens meaning they function normally.

Research Methodology

• The researchers started by examining whether equine monocyte-derived dendritic cells (DC), generated outside of a living organism (ex vivo), would be susceptible to EIAV infection. They infected these cells with the virus in a controlled environment (in vitro).
• They used immunofluorescence, a technique used for light microscopy with a fluorescence microscope, to detect EIAV antigen in infected DC. This was done 3 days post-infection and the maximum presence of antigen was recorded on the 4th day.
• Importantly, they compared the infected DC with control DC that were incubated with heat-inactivated EIAV which does not have infectious capabilities.

Key Findings

• No signs of cytolytic activity, cell death caused by the destruction of the cell’s membrane, were observed after DC were infected by EIAV. It suggests that DC can tolerate the presence of the virus without undergoing lysis (cell bursting).
• These infected DC were found to trigger a stronger reaction in stimulating allogenic T lymphocytes, responsible for cell-mediated immunity, compared to macrophages and B-cells.
• The researchers discovered that infected macrophages and infected DC stimulated similar memory cytotoxic T lymphocytes (CTL) responses in CD8+ and CD4+ cells mixtures. The CTL are immune cells crucial for viral control.

Implications of The Research

• The research indicates that EIAV infection in DC does not influence antigen presentation, which suggests that infection does not inhibit these cells’ immunogenic functionality.
• EIAV-infected DC were even observed to be more efficient than infected macrophages in stimulating memory CTL in isolated CD8+ cells. CD8+ cells are a type of T cell that can kill cancer cells and cells that are infected with viruses.
• Overall, this research suggests that the capability of antigen processing and presentation by DC might remain intact during a real, in vivo infection with EIAV. This contributes to our understanding of the disease mechanics and immune responses, and it may have implications in developing therapeutics for the EIAV.